The Clinical and Translation Allergy (CTA) has been lauched by EAACI in 2011 and it is EAACI's contribution to the most important way of publishing research - open access. With an impact factor of 3.539, CTA accepts scientific papers and reviews in the allergy field in both basic
and clinical research, and aims to provide a very rapid and fair peer-review process.
The co-editors in Chief, Jean Bousquet and Clive Grattan, aim to increase the impact of the journal by promoting excellent quality research but also
by promoting EAACI Junior Members as follows:
Discount for EAACI Junior Members when publishing
When publishing with CTA, EAACI Junior Members benefit from a 20% discount on the total manuscript fee. In addition EAACI will cover 50%
of the remaining costs of the publication.
The JMA Working Group is very pleased to announce a new collaboration with the Clinical and Translational Allergy (CTA) journal - the JMA-CTA Collaboration. CTA welcomes the active involvement of the younger members of the Academy. Find out more here.
To go to the journal's website, please click here